Trebananib (USAN);
Trebananib (genetical recombination) (JAN);
Tovasanib

C2794H4248N752O886S30

63470.2089

63510.14

MDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA
KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGKGG GGGAQQEECE
WDPWTCEHMG SGSATGGSGS TASSGSGSAT HQEECEWDPW TCEHMLE
(Disulfide bridge: 7-7', 10-10', 42-102, 148-206, 239-246, 275-282, 42'-102', 148'-206', 239'-246', 275'-282')

Antineoplastic, Angiogenesis inhibitor, Angiopoietin antagonist

Trebananib, which inhibits angiopoietin-1 and angiopoietin-2 binding to TIE2 tyrosine kinase receptor.

ANGPT1 [HSA:284] [KO:K05465]
ANGPT2 [HSA:285] [KO:K05466]